Related Experiment Video
Updated: Jul 10, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a
Chuanxi Fu1, Ming Wang, Jianhua Liang
1Guangzhou Centre for Disease Control and Prevention, Guangzhou, China.
Insights
The Lanzhou lamb rotavirus (LLR) vaccine showed 73.3% effectiveness against rotavirus gastroenteritis requiring hospitalization in children under 5. One dose was moderately effective, especially in older infants.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Gastroenterology
Background:
- Rotavirus gastroenteritis is a significant cause of hospitalization in children under 5 years old.
- Assessing the real-world vaccine effectiveness (VE) of available vaccines is crucial for public health strategies.
Purpose of the Study:
- To determine the vaccine effectiveness (VE) of the Lanzhou lamb rotavirus (LLR) vaccine.
- To evaluate LLR vaccine efficacy against rotavirus gastroenteritis necessitating hospitalization in children younger than 5 years.
Main Methods:
- A case-control study design was employed.
- Children hospitalized with rotavirus gastroenteritis between 2002 and 2004 were identified as cases.
- Cases were matched to 838 controls by gender, age, and community; vaccine effectiveness was calculated for one or more LLR vaccine doses.
Main Results:
- The LLR vaccine demonstrated a VE of 73.3% (95% CI, 61.2-81.6%) for one dose versus zero doses.
- VE was higher in children aged 12-23 months (80.9%) compared to those aged 2-11 months (60.0%).
Conclusions:
- A single dose of the Lanzhou lamb rotavirus vaccine is moderately effective in preventing rotavirus gastroenteritis requiring hospitalization.
- The vaccine's effectiveness is notable, particularly in children aged 12-23 months.
Abstract:
We sought to determine the vaccine effectiveness (VE) of Lanzhou lamb rotavirus (LLR) vaccine against rotavirus gastroenteritis in children <5 requiring hospitalization. Children hospitalized 2002-2004 with rotavirus gastroenteritis were matched by gender, age and community to 838 controls. VE was calculated for one or more doses of LLR vaccine with 95% confidence intervals (CI). For one dose versus zero doses, LLR vaccine VE was 73.3% (95% CI, range 61.2-81.6%). VE of one dose versus zero doses was higher in children 12-23 months than in children 2-11 months (80.9% versus 60.0%). We found one dose moderately effective in preventing rotavirus gastroenteritis requiring hospitalization.
